Japan Respiratory Disease Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Type (Viral, Bacterial, and Combination), By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, and Others), and Japan Respiratory Disease Vaccine Market Insights, Industry Trend, Forecasts to 2035.

Japan Respiratory Disease Vaccine Market Insights Forecasts to 2035

• The Japan Respiratory Disease Vaccine Market Size Was Estimated at USD 3286.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 1.8% from 2025 to 2035
• The Japan Respiratory Disease Vaccine Market Size is Expected to Reach USD 3997.9 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan Respiratory Disease Vaccine market is anticipated to reach USD 3997.9 million by 2035, growing at a CAGR of 1.8% from 2025 to 2035. The Japan respiratory disease vaccine market is driven by various factors, including rising incidence of respiratory diseases, increased demand for vaccines, rising aging population, rising awareness about disease prevention, and advancements in vaccine development.

Market Overview

Respiratory disease is a wide range of conditions that affect the respiratory tract, including airways, lungs, and related structures. These include diseases such as influenza, pneumococcal pneumonia, respiratory syncytial virus (RSV), COVID-19, and other viral or bacterial infections that affect the respiratory tract. Infections, smoking, air pollution, and genetic predispositions are some of the causes of these illnesses. Japan respiratory disease vaccine market is one segment of the pharmaceutical industry that engages in producing, manufacturing, and distributing vaccines aimed at preventing or reducing respiratory infections. The Japan respiratory market is experiencing rapid growth due to the rise in the aging population, and the aging population is more susceptible to respiratory disease, which creates the demand for more effective vaccines. Additionally, increased prevalence of respiratory disease due to high smoking rates, increasing air pollution, and rapid urbanization further contribute to the market expansion. Advances in vaccine technologies like mRNA and viral vector platforms provide an opportunity to enhance the efficacy and safety of vaccines and accelerate vaccine development.

Report Coverage

This research report categorizes the market for the Japan respiratory disease vaccine market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan respiratory disease vaccine market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan respiratory disease vaccine market.

Driving Factors

The Japanese respiratory disease vaccine market is witnessing robust expansion fueled by several factors such as demographic shifts, public health programs, and environmental pressures that seek to augment demand for effective respiratory immunization. Japan's fast-growing elderly population is more susceptible to respiratory illnesses, which creates demand for preventive vaccines like the flu. The rise in urbanization, exposure to air pollution, and high smoking rates leads to weakened lung health, which boosts the need for respiratory vaccines. The people are becoming more aware of the importance of respiratory health, which further expands the market growth. Additionally, technological advancements and government immunization programs play an important role in the expansion of the market.

Restraining Factors

The cost of vaccine development is due to strict regulations, time-consuming, which limit the market expansion. Additionally, some vaccines require cold chain storage but it is challenging in areas with poor infrastructure and resources.

Market Segmentation

The Japan respiratory disease vaccine market share is classified into type and infection.

• The viral segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan respiratory disease vaccine market is segmented by type into viral, bacterial, and combination. Among these, the viral segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segmental growth is attributed to its ability to elicit strong and lasting immune responses. Additionally, they play an important role in reducing disease burden and transmission.

• The COVID-19 segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.

The Japan respiratory disease vaccine market is segmented by infection into COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and others. Among these, the COVID-19 segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to increased public awareness and government vaccination campaigns. Additionally, they help to maintain immunity.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan respiratory disease vaccine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• Moderna, Inc.
• AstraZeneca
• Sanofi
• GSK plc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Merck Sharp & Dohme Corp.
• Other

Recent Developments

• In June 2025, Japan’s Ministry of Health has accepted GSK’s regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18–49 at increased risk of severe disease.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan respiratory disease vaccine market based on the below-mentioned segments:

Japan Respiratory Disease Vaccine Market, By Type

• Viral
• Bacterial
• Combination

Japan Respiratory Disease Vaccine Market, By Infection

• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Pneumonia
• Others